Phenylketonuria

For PAH c.1174T>A (p.Phe392Ile), a pathogenic missense variant in the tetramerization domain of phenylalanine hydroxylase, sapropterin dihydrochloride (Kuvan, BioMarin) — a synthetic formulation of the natural PAH cofactor tetrahydrobiopterin (BH4) — represents a genotype-guided oral pharmacological therapy. Sapropterin acts as both a cofactor supplement and pharmacological chaperone, stabilizing the misfolded PAH protein and enhancing residual enzymatic activity. Phe392 is located at the interface between the catalytic and tetramerization domains; the F392I substitution destabilizes the tetrameric quaternary structure required for full enzymatic activity. BH4-responsive variants are typically missense mutations that retain some folding capacity — the mutant protein is produced but unstable, and BH4 binding thermodynamically stabilizes the active conformation.

Sapropterin received FDA approval in 2007 for BH4-responsive PKU based on the PKU-001 and PKU-003 Phase 3 trials, which demonstrated significant blood Phe reduction in responsive patients (PMID: 17576681). BH4 responsiveness is genotype-dependent: approximately 25-50% of PKU patients carry at least one BH4-responsive allele. The BioPKU database catalogs PAH genotype-phenotype correlations and BH4 responsiveness predictions for individual variants. For p.Phe392Ile specifically, structural modeling predicts that BH4 binding at the active site stabilizes the catalytic domain fold and indirectly supports tetramerization. In vitro expression studies and clinical BH4 loading tests are the standard methods for confirming responsiveness. Pegvaliase (Palynziq), a PEGylated recombinant phenylalanine ammonia lyase (enzyme substitution therapy), provides an alternative mechanism for Phe reduction in patients who are BH4-non-responsive, achieving blood Phe normalization regardless of genotype.

Sapropterin response is inherently genotype-dependent and only partially effective: most responsive patients achieve 30-50% Phe reduction, often requiring continued dietary phenylalanine restriction (though less stringent than without treatment). Complete normalization of blood Phe on sapropterin alone is uncommon. For p.Phe392Ile, BH4 responsiveness must be confirmed empirically via a BH4 loading test (typically 20 mg/kg/day for 24-48 hours with serial Phe measurements), as in silico predictions are not fully reliable. The tetramerization domain location of this variant may limit BH4 chaperone efficacy since BH4 binds the active site rather than the tetramerization interface — stabilization is indirect. Sapropterin costs approximately $100,000-200,000/year and requires lifelong daily oral administration. Patients homozygous for null variants (frameshifts, nonsense, large deletions) are universally BH4-non-responsive because there is no protein to stabilize. For these patients, pegvaliase or gene therapy approaches are more appropriate.

For PAH c.1316-1G>A, a canonical splice acceptor variant predicted to abolish normal exon 12 inclusion and produce non-functional PAH enzyme, liver-directed AAV gene therapy delivering a functional PAH transgene is a rational therapeutic approach. This variant disrupts the invariant AG dinucleotide at the exon 12 splice acceptor site, expected to cause exon skipping or intron retention and consequent loss of phenylalanine hydroxylase activity. Because splice-site variants are not amenable to simple base editing (unlike point missense variants), gene addition via AAV is the most straightforward precision medicine approach for this allele. Multiple AAV-PAH programs are in preclinical to early clinical development, with mouse models demonstrating sustained normalization of blood phenylalanine following liver-directed AAV5 or AAV8 gene transfer.

AAV-mediated liver-directed PAH gene addition has shown preclinical proof-of-concept in Pah-enu2 mice, with sustained phenylalanine normalization lasting months after a single administration (Viecelli et al., Nat Med 2014; PMID:25100528). BioMarin BMN 307 (AAV5-PAH) entered Phase 1/2 clinical trials (NCT04480567), representing the most advanced AAV gene therapy for PKU, though the program was subsequently paused. Additional approaches using mRNA-LNP for transient PAH expression are in development (Brooks et al., HGG Adv 2024; PMID:37922902). For c.1316-1G>A specifically, this splice-site variant is classified as Pathogenic in ClinVar. The invariant G at position -1 of the splice acceptor is critical for spliceosome recognition; G>A substitution at this position has well-established precedent across multiple genes for causing complete exon skipping. In compound heterozygotes, the second allele genotype modulates phenotype severity, but patients homozygous or compound heterozygous for null alleles like splice-site variants typically present with classical PKU requiring strict dietary phenylalanine restriction.

BMN 307, the most advanced AAV-PAH program, was paused due to hepatocellular carcinoma signals in a mouse study, raising concerns about insertional mutagenesis risk with AAV integration in dividing hepatocytes. Whether these mouse findings translate to human risk remains debated, as the Pah-enu2 mouse model has inherent liver pathology. Pre-existing anti-AAV antibodies exclude a significant fraction of patients from AAV gene therapy. Transgene expression durability is uncertain — episomal AAV genomes may be diluted with hepatocyte turnover, particularly in pediatric patients with growing livers, potentially requiring retreatment that is precluded by anti-AAV immunity. For a splice-site variant like c.1316-1G>A, direct correction approaches (e.g., U1 snRNA modification or splice-switching ASOs) could theoretically restore normal splicing but remain preclinical. The dietary management alternative, while burdensome, is effective at preventing intellectual disability if initiated early, making the risk-benefit calculus for gene therapy more complex than for diseases without existing treatment options.

For PAH c.1161C>A (p.Tyr387Ter), a nonsense variant in exon 11 that abolishes phenylalanine hydroxylase activity, adenine base editing (ABE) delivered via lipid nanoparticles (LNPs) to hepatocytes represents a potentially curative one-dose approach. The variant creates a TAA stop codon (c.1161C>A changes UAC→UAA on the mRNA); on the antisense strand, the target adenine in the TAG complement can be converted to guanine by ABE (A→G on antisense = T→C on sense), reverting the stop codon to a sense codon. This strategy leverages the established hepatotropism of LNPs and avoids the immunogenicity concerns of AAV-based delivery, while potentially achieving durable correction through editing of long-lived hepatocytes.

Brooks et al. (HGG Adv 2024; PMID:37922902) demonstrated that mRNA-LNP delivery of an adenine base editor with an optimized guide RNA achieved sufficient PAH editing in mouse hepatocytes to fully normalize blood phenylalanine levels within 48 hours of a single intravenous dose in c.1222C>T humanized PKU mice. While that study targeted the R408W variant, the ABE platform is adaptable to other PAH stop codons where the target adenine falls within the ABE editing window (positions 4-8 of the protospacer). Villiger et al. (Nat Med 2021; PMID:33707775) showed that AAV-delivered ABE corrected the PAH c.835T>C variant in Pah-enu2 mice with sustained phenylalanine normalization over 26 weeks. For p.Tyr387Ter specifically, ClinVar classifies this variant as Pathogenic. Tyr387 is located in the catalytic domain of PAH near the active site; restoration of any amino acid compatible with PAH folding at this position would be therapeutic — ABE would convert the stop to a glutamine (TAG→CAG on antisense), arginine, or other amino acid depending on the editing window, and in silico tolerance prediction suggests multiple substitutions at position 387 retain enzymatic activity.

The specific base editing strategy for c.1161C>A (p.Tyr387Ter) has not been experimentally validated — this analysis extrapolates from the proven ABE-LNP platform applied to other PAH variants. The editing product amino acid (determined by the specific A-to-G conversion within the editing window) must be verified as compatible with PAH enzymatic function; not all amino acid substitutions at position 387 may retain activity. LNP delivery achieves high liver tropism but editing efficiency in non-human primates is lower than in mice — clinical translation requires demonstration of sufficient hepatocyte editing (estimated >5-10% correction needed for metabolic normalization based on enzyme kinetics). LNP immunogenicity after repeated dosing is a concern if the initial editing efficiency is subtherapeutic, though ideally a single dose achieves sufficient correction. Off-target editing (both DNA off-targets and RNA editing by ABE deaminase) requires thorough safety characterization. For compound heterozygous patients with one copy of p.Tyr387Ter and a different PAH variant on the other allele, correcting one allele may be sufficient given the recessive inheritance of PKU — but this depends on the residual activity of the second allele.

Two distinct nucleic acid therapy strategies are being developed for PKU: (1) LNP-encapsulated mRNA encoding PAH (ARCT-810, Arcturus Therapeutics) for repeated hepatic PAH restoration, and (2) AAV5-mediated PAH gene replacement (BMN 307, BioMarin) for durable one-time correction. The c.1259G>T (p.Arg420Met) missense variant in the catalytic domain likely disrupts tetrahydrobiopterin (BH4) binding or catalytic geometry, resulting in reduced but potentially not absent enzymatic activity. Both strategies could benefit this variant, though the residual activity profile may also make it a candidate for BH4-responsive therapy (sapropterin).

PAH (phenylalanine hydroxylase) is a hepatic enzyme that converts L-phenylalanine to L-tyrosine using BH4 as cofactor. The p.Arg420Met substitution occurs in the catalytic domain (residues ~118-427), where Arg420 participates in positioning the active-site iron and BH4 cofactor. Arcturus Therapeutics developed ARCT-810 using their LUNAR lipid nanoparticle platform to deliver codon-optimized PAH mRNA to hepatocytes. In the Pah^enu2 mouse model, a single IV dose of LNP-PAH mRNA reduced blood phenylalanine levels substantially within 24 hours. A Phase 1 clinical trial (NCT04442347) was initiated. BioMarin BMN 307 uses AAV5 with a liver-specific promoter to drive durable PAH expression; however, preclinical studies raised safety concerns when AAV vector integration was associated with hepatocellular carcinoma in mouse long-term studies, resulting in an FDA clinical hold. Separately, enzyme substitution (pegvaliase/Palynziq, FDA-approved 2018) provides a non-genetic therapeutic comparator.

For mRNA therapy (ARCT-810): requires repeated IV dosing (likely every 2-4 weeks), potential for anti-LNP immune responses limiting re-dosing efficacy, and transient rather than durable correction. For AAV gene therapy (BMN 307): the FDA clinical hold due to insertional mutagenesis concerns is a significant safety signal, and the long-term oncogenic risk of liver-directed AAV in humans remains under investigation. The p.Arg420Met variant may retain partial catalytic activity — genotype-phenotype correlation in PKU is complex, and some missense variants respond to BH4 supplementation (sapropterin), potentially making gene/RNA therapy unnecessary for this specific variant if BH4-responsiveness is confirmed. Neither ARCT-810 nor BMN 307 has reported variant-stratified efficacy data.

Base Editing (ABE8e) via LNP delivery is a rationale-driven therapeutic strategy for Phenylketonuria targeting the PAH c.865G>A (p.Gly289Arg) variant (Pathogenic, missense variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Liver. Therapeutic goal: Correct PAH Arg408Trp and similar loss-of-function variants in hepatocytes to restore sufficient PAH activity and normalize systemic phenylalanine levels, preventing neurotoxicity.. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Low, immunogenicity Low.

1. Molecular basis: PAH NM_000277.3(PAH):c.865G>A (p.Gly289Arg) is classified as Pathogenic (ClinVar variation ID 458082). Molecular consequence: missense variant. Protein change: G289R. 2. Epidemiology: Global birth prevalence of PAH-deficient PKU is ~1:16,000–1:24,000 newborns, with higher rates in certain countries (e.g., up to ~1:4,000 in parts of the Middle East) and routine newborn screening in most high-income regions. 3. Standard of care: Lifelong low-phenylalanine diet with medical foods started in the neonatal period, with adjunctive pharmacologic options in subsets of patients including sapropterin or sepiapterin (for BH4-responsive PAH deficiency) and pegvaliase enzyme substitution for adults with uncontrolled Phe. 4. Pipeline: Multiple liver-directed AAV gene-addition therapies for PAH are in preclinical to Phase I/II trials; mRNA/LNP and in vivo base-editing approaches correcting common PAH variants have shown metabolic cure in mouse models but have not yet entered human gene-editing trials as of the latest evidence. 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting PAH c.865G>A (p.Gly289Arg) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.

AAV-mediated PAH gene replacement in hepatocytes is the leading curative strategy for classical PKU, including variants like p.His170Gln that severely impair enzyme activity. His170 is located in the catalytic domain and coordinates with the iron cofactor essential for phenylalanine hydroxylation; its substitution to glutamine abolishes enzymatic function. Because PKU pathology stems entirely from hepatic PAH deficiency, liver-targeted gene therapy can in principle normalize systemic phenylalanine levels regardless of the specific underlying mutation. Multiple AAV-PAH programs have advanced to clinical trials, including BMN 307 (BioMarin, AAV5-PAH) which demonstrated dose-dependent Phe reductions in Phase 1/2.

BioMarin reported Phase 1/2 results for BMN 307 (AAV5 carrying human PAH cDNA under a liver-specific promoter) showing dose-dependent blood phenylalanine reductions in adult PKU patients, though the magnitude and durability of Phe lowering were variable across dose cohorts. Preclinical studies in Pah-enu2 mice (the standard PKU model carrying a missense mutation at the equivalent catalytic domain position) have consistently shown that AAV-mediated hepatic PAH expression normalizes blood Phe and reverses hypopigmentation. The PAH gene (2.5 kb coding sequence) fits comfortably within AAV packaging limits. Structural studies confirm His170 participates in the active-site iron coordination sphere (PDB: 1PAH), and H170Q disrupts the catalytic geometry required for tetrahydrobiopterin-dependent hydroxylation.

AAV-mediated liver gene therapy faces several unresolved challenges for PKU. Pre-existing anti-AAV5 neutralizing antibodies exclude a substantial fraction of adult patients. Transgene expression from episomal AAV genomes can decline over years as hepatocytes turn over, potentially requiring re-dosing — but anti-capsid immunity precludes re-administration with the same serotype. BioMarin paused BMN 307 development in 2023 citing the evolving competitive landscape rather than safety failure, creating uncertainty about the commercial viability of this approach. Immunosuppression regimens needed to manage capsid-directed T-cell responses add complexity, especially for a non-life-threatening condition where the risk-benefit calculus differs from lethal diseases. mRNA-based approaches (e.g., lipid nanoparticle-delivered PAH mRNA) are emerging as alternatives that allow repeat dosing but require chronic administration.